Company Overview
Snapshot
Founded in June 2019 by Gil Shapira and Moshe Eshkol, Squalus Medical operates with 1–10 employees. The company has raised $1 million across one funding round and received a grant in January 2021 from the BIRD Foundation.
Business overview
Squalus Medical is advancing medical technology with a laser-based thermal ablation system designed to treat previously inoperable cases of epilepsy and enhance existing procedural outcomes. Its core product, the StingRay Laser System, integrates fiber-optic technology with an advanced laser console. This system is engineered to precisely match the epileptic focal source and energy delivery while safeguarding vital functional areas from thermal damage. The console also features computer-vision analysis to guide physicians, ensuring treatments are tailored to specific patient needs and clinical requirements. Squalus Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.
Strategic signal
In January 2021, the BIRD Foundation announced its investment in Squalus Medical as part of a broader initiative to fund eight new projects with a total of $7.45 million. This grant signals external validation of Squalus Medical's innovative approach to epilepsy treatment and its potential to address significant unmet medical needs, positioning the company for continued R&D and product development.
Log in to access full profile ›Company Intelligence Q&A
- What is Squalus Medical's primary focus?
- Squalus Medical is developing a laser-based thermal ablation technology for treating epilepsy, particularly for cases that were previously considered inoperable, and to improve the outcomes of current procedures.
- When was Squalus Medical founded and by whom?
- Squalus Medical was founded in June 2019 by Gil Shapira and Moshe Eshkol.
- What is the StingRay Laser System?
- The StingRay Laser System is Squalus Medical's core product, combining fiber-optic technology with an advanced laser console that precisely targets epileptic focal sources and delivers energy while protecting vital functional areas. It also integrates computer-vision for physician guidance.
- Has Squalus Medical received any grants?
- In January 2021, Squalus Medical received a grant from the BIRD Foundation, which was part of a larger investment of $7.45 million across eight new projects.
- What is Squalus Medical's current product development stage?
- Squalus Medical's StingRay Laser System is currently in the R&D product stage, focusing on developing its laser-based thermal ablation system for epilepsy treatment.